SCHEMBL6890889

SCHEMBL6890889

Cc1nc(C(=O)CO)c2sccn12

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.38
DYRK1A Q13627 1/20 0.36
CYP1A2 P05177 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALOX12 P18054 1/20 0.35
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
RECQL P46063 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALOX15 P16050 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890415 0.82 KDM4E (0.41) MAPK1DYRK1ACYP1A2TDP1ALOX12
SCHEMBL6894574 0.81 MAPK1 (0.40) MAPK1CYP1A2TDP1ALOX12KDM4E
SCHEMBL6892437 0.78 MAPK1 (0.35) MAPK1CYP1A2TDP1KDM4EALDH1A1
SCHEMBL10512497 0.70 MAPK1 (0.64) MAPK1DYRK1ACYP1A2TDP1ALOX12
SCHEMBL13377455 0.68 CYP1A2 (0.40) MAPK1DYRK1ACYP1A2TDP1ALOX12
SCHEMBL6771028 0.67 ALOX12 (0.38) MAPK1CYP1A2TDP1ALOX12
SCHEMBL6891044 0.67 CYP1A2 (0.36) MAPK1CYP1A2TDP1ALOX12KDM4E
SCHEMBL6771198 0.65 ALOX12 (0.36) MAPK1CYP1A2TDP1ALOX12
SCHEMBL1339860 0.61 CYP1A2 (0.47) MAPK1DYRK1ACYP1A2TDP1ALOX12
SCHEMBL10340126 0.60 DYRK1A (0.65) MAPK1DYRK1ACYP1A2TDP1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 MAPK1 1333/4885DYRK1A 1789/4885CYP1A2 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.